BioPharma Dive June 24, 2024
The American Diabetes Association’s annual meeting provided a forum for early trial results on several would-be weight loss drug competitors.
Today, a brief rundown of news from Altimmune, Jiangsu Hengrui, Eli Lilly and others that you might have missed from over the weekend, when the American Diabetes Association held its annual meeting.
After an early setback for Altimmune’s obesity shot pemvidutide, the biotechnology company appears to be back on track with additional data. The dual-acting drug, which stimulates the hormones GLP-1 and glucagon, helped participants in the Momentum trial lose an average of 16% of their body weight at the highest dose given, according to full trial results presented at ADA. That weight loss at 48 weeks is in line...